Celularity Inc. Form 8-K Summary
Business Context and Reporting Period
Celularity Inc. (CELU), a Delaware corporation, filed this Current Report on Form 8-K on December 27, 2024. The filing reports the entry into a Material Definitive Agreement and the unregistered sale of equity securities via a private placement with an institutional investor.
Key Financial Metrics and Transaction Details
- Transaction Type: Private placement of Class A Common Stock and Common Warrants.
- Securities Issued: 1,263,157 shares of Common Stock and warrants to purchase an equal number of shares.
- Purchase Price: $2.375 per share of Common Stock and accompanying warrants.
- Expected Gross Proceeds: $3.0 million (before estimated offering expenses).
- Warrant Terms: Exercise price of $2.97 per share; exercisable beginning six months after issuance; five-year term.
- Ownership Limitation: Warrant holders cannot exercise to own more than 4.99% (or 9.99% at election) of outstanding common stock.
- Use of Proceeds: Working capital and general corporate purposes.
Note: This filing does not provide revenue, profit, cash flow, margin, or debt metrics for the company's ongoing operations.
Material Changes and Closing Conditions
The Company entered into a Securities Purchase Agreement and a Registration Rights Agreement. The closing is expected during the week of January 6, 2025, subject to customary conditions. Under the Registration Rights Agreement, Celularity must file a registration statement for the resale of the securities within 45 days of closing and use commercially reasonable efforts to have it declared effective within 120 days.
Outlook, Risks, and Management Commentary
Management intends to utilize the net proceeds to support working capital and general corporate needs. The filing notes that the descriptions of the agreements are qualified by the full text of the exhibits attached to the report. No specific forward-looking guidance regarding product development or clinical trials is included in this specific filing.
Key Facts for Investor Verification
- Confirm the actual closing date of the private placement (expected week of January 6, 2025).
- Verify the final net proceeds after deducting offering expenses.
- Monitor the filing and effectiveness of the registration statement for the resale of shares (due within 45-120 days of closing).
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific termination provisions and representations.